B. Metzler seel. Sohn & Co. AG Sells 59,979 Shares of Boston Scientific Co. (NYSE:BSX)

B. Metzler seel. Sohn & Co. AG lowered its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 21.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 225,711 shares of the medical equipment provider's stock after selling 59,979 shares during the quarter. B. Metzler seel. Sohn & Co. AG's holdings in Boston Scientific were worth $20,167,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of the stock. D.A. Davidson & CO. increased its position in shares of Boston Scientific by 3.2% during the third quarter. D.A. Davidson & CO. now owns 10,945 shares of the medical equipment provider's stock valued at $917,000 after purchasing an additional 342 shares during the period. Townsquare Capital LLC boosted its stake in Boston Scientific by 191.9% during the third quarter. Townsquare Capital LLC now owns 26,896 shares of the medical equipment provider's stock worth $2,254,000 after buying an additional 17,683 shares in the last quarter. Glenmede Trust Co. NA raised its stake in shares of Boston Scientific by 19.0% in the 3rd quarter. Glenmede Trust Co. NA now owns 20,463 shares of the medical equipment provider's stock valued at $1,715,000 after buying an additional 3,261 shares in the last quarter. CreativeOne Wealth LLC lifted its holdings in shares of Boston Scientific by 62.0% during the 3rd quarter. CreativeOne Wealth LLC now owns 4,478 shares of the medical equipment provider's stock worth $375,000 after acquiring an additional 1,714 shares during the period. Finally, Hantz Financial Services Inc. boosted its position in shares of Boston Scientific by 0.8% during the 3rd quarter. Hantz Financial Services Inc. now owns 33,367 shares of the medical equipment provider's stock valued at $2,796,000 after acquiring an additional 263 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Boston Scientific Stock Down 7.5 %

Shares of Boston Scientific stock traded down $7.41 during trading hours on Friday, reaching $91.09. 10,199,711 shares of the company's stock were exchanged, compared to its average volume of 6,137,618. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The company has a 50 day moving average of $102.14 and a two-hundred day moving average of $93.51. The stock has a market cap of $134.73 billion, a P/E ratio of 72.74, a P/E/G ratio of 2.79 and a beta of 0.77. Boston Scientific Co. has a fifty-two week low of $66.80 and a fifty-two week high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, sell-side analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on BSX shares. Barclays raised their target price on Boston Scientific from $111.00 to $118.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. UBS Group lifted their price objective on Boston Scientific from $105.00 to $130.00 and gave the company a "buy" rating in a report on Friday, February 7th. Piper Sandler upped their target price on shares of Boston Scientific from $95.00 to $115.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. StockNews.com downgraded shares of Boston Scientific from a "buy" rating to a "hold" rating in a report on Saturday, March 8th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a research note on Friday, January 10th. Two research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Boston Scientific has an average rating of "Moderate Buy" and a consensus price target of $108.91.

Insiders Place Their Bets

In other news, EVP John Bradley Sorenson sold 6,528 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $104.97, for a total value of $685,244.16. Following the completion of the sale, the executive vice president now directly owns 26,449 shares of the company's stock, valued at $2,776,351.53. This trade represents a 19.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $101.80, for a total value of $1,762,463.40. Following the sale, the executive vice president now directly owns 5,502 shares of the company's stock, valued at $560,103.60. This represents a 75.88 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 133,183 shares of company stock valued at $13,948,476. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.